Viatris Reports Strong Q1 2026 Earnings with $3.5 Billion Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy VTRS?
Source: seekingalpha
- Strong Financial Performance: Viatris reported total revenues of $3.5 billion in Q1 2026, reflecting a 3% year-over-year increase, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59, indicating robust growth and profitability in the market.
- Regional Growth Drivers: The cardiovascular portfolio in Greater China drove an 18% year-over-year growth, while e-commerce sales more than doubled, enhancing the company's competitive position in the rapidly growing Asia-Pacific market and laying a foundation for future revenue growth.
- Pipeline Progress: The NDA for fast-acting meloxicam has been accepted for FDA review, with regulatory decisions expected in the second half of 2026, while the PDUFA goal dates for XULANE LO and presbyopia treatment are set for July 30 and October 17, 2026, respectively, showcasing the company's ongoing commitment to innovative drug development.
- Leadership Change and Outlook: Interim CFO Paul Campbell has taken over from former CFO Doretta Mistras, with management reaffirming confidence in their 2026 financial guidance, expecting mid- to high-single-digit growth in Greater China despite policy risks and competitive pressures in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 17.390
Low
10.00
Averages
13.25
High
16.00
Current: 17.390
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HHS Considers Restrictions on Antidepressant Use Amid Mental Health Crisis
- Mental Health Crisis Response: HHS announced the launch of the 'MAHA Action Plan' at the Mental Health and Overmedicalization Summit, aimed at addressing the overprescription of psychiatric medications, particularly among children, highlighting a commitment to improving mental health.
- Current Medication Usage: A 2026 study revealed that 16.6% of Americans are taking antidepressants, indicating the prevalence of these medications and their significant impact on public health.
- Shift in Policy Direction: HHS Secretary RFK Jr. emphasized a future shift in treatment standards towards prevention, transparency, and a more holistic approach, supporting patient autonomy and informed consent, reflecting a reevaluation of mental health treatment methods.
- SSRIs Ban Discussion: Despite discussions about potentially banning selective serotonin reuptake inhibitors (SSRIs), an HHS spokesperson clarified that no such discussions have taken place, indicating uncertainty in the policy-making process.
See More
Viatris to Present at Bank of America Healthcare Conference
- Conference Schedule: Viatris Inc. will present at the Bank of America Securities 2026 Healthcare Conference on May 12, 2026, at 8 a.m. PT / 11 a.m. ET, providing updates to investors and the public about the company's latest developments.
- Live and Archived Access: The event will feature a live webcast accessible via viatris.com, and an archived version will be available post-event, ensuring that investors who cannot attend live can still access important information.
- Company Mission and Vision: Viatris aims to empower people worldwide to live healthier at every stage of life, demonstrating its commitment to meeting global patient needs through innovation and resolve, thereby showcasing its impact in the healthcare sector.
- Global Presence: Headquartered in the U.S., Viatris has global centers in Shanghai, China, and Hyderabad, India, highlighting its business expansion and focus on diverse markets around the world.
See More
Viatris Reports Strong Q1 2026 Earnings with $3.5 Billion Revenue
- Strong Financial Performance: Viatris reported total revenues of $3.5 billion in Q1 2026, reflecting a 3% year-over-year increase, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59, indicating robust growth and profitability in the market.
- Regional Growth Drivers: The cardiovascular portfolio in Greater China drove an 18% year-over-year growth, while e-commerce sales more than doubled, enhancing the company's competitive position in the rapidly growing Asia-Pacific market and laying a foundation for future revenue growth.
- Pipeline Progress: The NDA for fast-acting meloxicam has been accepted for FDA review, with regulatory decisions expected in the second half of 2026, while the PDUFA goal dates for XULANE LO and presbyopia treatment are set for July 30 and October 17, 2026, respectively, showcasing the company's ongoing commitment to innovative drug development.
- Leadership Change and Outlook: Interim CFO Paul Campbell has taken over from former CFO Doretta Mistras, with management reaffirming confidence in their 2026 financial guidance, expecting mid- to high-single-digit growth in Greater China despite policy risks and competitive pressures in the market.
See More
Viatris Reaffirms Full-Year Outlook, Shares Surge
- Strong Earnings Beat: Viatris reported $3.5 billion in revenue for Q1 2026, exceeding consensus by $150 million with approximately 8% year-over-year growth, marking its third consecutive quarter of growth and indicating robust business recovery momentum.
- Brand Segment Growth: The Brands segment contributed $2.3 billion to revenue with around 10% year-over-year growth, driven by acceleration in Greater China and strength in Emerging Markets, further solidifying Viatris's competitive position globally.
- Profitability Improvement: The adjusted gross margin remained steady at 56%, while adjusted EBITDA and adjusted earnings per share increased by 14% and approximately 18% year-over-year to $1.0 billion and $0.59, respectively, surpassing analyst expectations and reflecting effective cost management and profitability enhancement.
- Full-Year Guidance Reaffirmed: Although the midpoint of adjusted EPS guidance at $2.40 fell short of the consensus of $2.44, the 2026 revenue guidance of $14.450 billion to $14.950 billion exceeded analyst projections, demonstrating the company's confidence in future growth.
See More
Viatris Executive Anticipates Mid to High Single-Digit Revenue Growth in Greater China by 2026 - Conference Call
Revenue Growth Expectations: Viasat executives anticipate significant growth in single-digit revenue in China by 2026.
Market Insights: The company's confidence in revenue growth is based on current market trends and demand in the region.
See More
Viatris Q1 Earnings Exceed Expectations
- Earnings Highlights: Viatris reported a Q1 non-GAAP EPS of $0.59, beating expectations by $0.09, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Revenue Growth: The company achieved Q1 revenue of $3.51 billion, an 8.0% year-over-year increase, exceeding market expectations by $150 million, indicating robust demand and competitive positioning in the market.
- 2026 Guidance: Viatris projects FY26 revenue of $14.64 billion and adjusted EPS of $2.44, demonstrating confidence in future growth despite market caution regarding its long-term strategy and turnaround efforts.
- Free Cash Flow Outlook: The expected free cash flow for 2026 ranges from $1.95 billion to $2.35 billion, with a midpoint of $2.15 billion, providing essential funding for future investments and strategic restructuring initiatives.
See More
HHS Considers Restrictions on Antidepressant Use Amid Mental Health Crisis
- Mental Health Crisis Response: HHS announced the launch of the 'MAHA Action Plan' at the Mental Health and Overmedicalization Summit, aimed at addressing the overprescription of psychiatric medications, particularly among children, highlighting a commitment to improving mental health.
- Current Medication Usage: A 2026 study revealed that 16.6% of Americans are taking antidepressants, indicating the prevalence of these medications and their significant impact on public health.
- Shift in Policy Direction: HHS Secretary RFK Jr. emphasized a future shift in treatment standards towards prevention, transparency, and a more holistic approach, supporting patient autonomy and informed consent, reflecting a reevaluation of mental health treatment methods.
- SSRIs Ban Discussion: Despite discussions about potentially banning selective serotonin reuptake inhibitors (SSRIs), an HHS spokesperson clarified that no such discussions have taken place, indicating uncertainty in the policy-making process.
See More
Viatris to Present at Bank of America Healthcare Conference
- Conference Schedule: Viatris Inc. will present at the Bank of America Securities 2026 Healthcare Conference on May 12, 2026, at 8 a.m. PT / 11 a.m. ET, providing updates to investors and the public about the company's latest developments.
- Live and Archived Access: The event will feature a live webcast accessible via viatris.com, and an archived version will be available post-event, ensuring that investors who cannot attend live can still access important information.
- Company Mission and Vision: Viatris aims to empower people worldwide to live healthier at every stage of life, demonstrating its commitment to meeting global patient needs through innovation and resolve, thereby showcasing its impact in the healthcare sector.
- Global Presence: Headquartered in the U.S., Viatris has global centers in Shanghai, China, and Hyderabad, India, highlighting its business expansion and focus on diverse markets around the world.
See More
Viatris Reports Strong Q1 2026 Earnings with $3.5 Billion Revenue
- Strong Financial Performance: Viatris reported total revenues of $3.5 billion in Q1 2026, reflecting a 3% year-over-year increase, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59, indicating robust growth and profitability in the market.
- Regional Growth Drivers: The cardiovascular portfolio in Greater China drove an 18% year-over-year growth, while e-commerce sales more than doubled, enhancing the company's competitive position in the rapidly growing Asia-Pacific market and laying a foundation for future revenue growth.
- Pipeline Progress: The NDA for fast-acting meloxicam has been accepted for FDA review, with regulatory decisions expected in the second half of 2026, while the PDUFA goal dates for XULANE LO and presbyopia treatment are set for July 30 and October 17, 2026, respectively, showcasing the company's ongoing commitment to innovative drug development.
- Leadership Change and Outlook: Interim CFO Paul Campbell has taken over from former CFO Doretta Mistras, with management reaffirming confidence in their 2026 financial guidance, expecting mid- to high-single-digit growth in Greater China despite policy risks and competitive pressures in the market.
See More
Viatris Reaffirms Full-Year Outlook, Shares Surge
- Strong Earnings Beat: Viatris reported $3.5 billion in revenue for Q1 2026, exceeding consensus by $150 million with approximately 8% year-over-year growth, marking its third consecutive quarter of growth and indicating robust business recovery momentum.
- Brand Segment Growth: The Brands segment contributed $2.3 billion to revenue with around 10% year-over-year growth, driven by acceleration in Greater China and strength in Emerging Markets, further solidifying Viatris's competitive position globally.
- Profitability Improvement: The adjusted gross margin remained steady at 56%, while adjusted EBITDA and adjusted earnings per share increased by 14% and approximately 18% year-over-year to $1.0 billion and $0.59, respectively, surpassing analyst expectations and reflecting effective cost management and profitability enhancement.
- Full-Year Guidance Reaffirmed: Although the midpoint of adjusted EPS guidance at $2.40 fell short of the consensus of $2.44, the 2026 revenue guidance of $14.450 billion to $14.950 billion exceeded analyst projections, demonstrating the company's confidence in future growth.
See More
Viatris Executive Anticipates Mid to High Single-Digit Revenue Growth in Greater China by 2026 - Conference Call
Revenue Growth Expectations: Viasat executives anticipate significant growth in single-digit revenue in China by 2026.
Market Insights: The company's confidence in revenue growth is based on current market trends and demand in the region.
See More
Viatris Q1 Earnings Exceed Expectations
- Earnings Highlights: Viatris reported a Q1 non-GAAP EPS of $0.59, beating expectations by $0.09, which reflects strong profitability and boosts investor confidence in the company's financial health.
- Revenue Growth: The company achieved Q1 revenue of $3.51 billion, an 8.0% year-over-year increase, exceeding market expectations by $150 million, indicating robust demand and competitive positioning in the market.
- 2026 Guidance: Viatris projects FY26 revenue of $14.64 billion and adjusted EPS of $2.44, demonstrating confidence in future growth despite market caution regarding its long-term strategy and turnaround efforts.
- Free Cash Flow Outlook: The expected free cash flow for 2026 ranges from $1.95 billion to $2.35 billion, with a midpoint of $2.15 billion, providing essential funding for future investments and strategic restructuring initiatives.
See More
